Sichuan Kelun Pharmaceutical Co Ltd Total Assets

Latest as of June 2026: CN¥41.49 Billion CNY ≈ $6.07 Billion USD

Sichuan Kelun Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) holds total assets worth CN¥41.49 Billion CNY (≈ $6.07 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Sichuan Kelun Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.

Total Assets of Sichuan Kelun Pharmaceutical Co Ltd (2007–2025)

Total assets of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002422 live share price for real-time trading data and today's change.

Sichuan Kelun Pharmaceutical Co Ltd - Asset Composition Analysis

Sichuan Kelun Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)

Sichuan Kelun Pharmaceutical Co Ltd total assets breakdown as of December 2025. Sichuan Kelun Pharmaceutical Co Ltd's total assets of CN¥41.49 Billion consist of 50.3% current assets and 49.7% non-current assets. Explore 002422 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 15.1%
Accounts Receivable CN¥4.67 Billion 11.7%
Inventory CN¥3.85 Billion 9.7%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥1.23 Billion 3.1%
Goodwill CN¥96.25 Million 0.2%

Asset Composition Trend (2007–2025)

This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Sichuan Kelun Pharmaceutical Co Ltd's current assets represent 50.3% of total assets in 2025, a decrease from 61.8% in 2007.
  • Cash Position: Cash and equivalents constituted 15.1% of total assets in 2025, up from 5.8% in 2007.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2007.
  • Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.

Sichuan Kelun Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Sichuan Kelun Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
AstraZeneca PLC
MX:AZNN
Mexico MX$114.07 Billion
AstraZeneca PLC
LSE:AZN
UK GBX116.43 Billion
AbbVie Inc
NYSE:ABBV
USA $136.46 Billion
Pfizer Inc
NYSE:PFE
USA $201.13 Billion
Novo Nordisk A/S
CO:NOVO-B
Denmark Dkr542.90 Billion
Merck & Company Inc
NYSE:MRK
USA $129.80 Billion
AstraZeneca PLC
NASDAQ:AZN
USA $114.02 Billion
Novartis AG
MX:NVSN
Mexico MX$118.53 Billion

Sichuan Kelun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.09 2.16 1.06
Quick Ratio 1.72 1.76 0.81
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥11.37 Billion CN¥10.51 Billion CN¥749.63 Million

Sichuan Kelun Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Sichuan Kelun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.54
Latest Market Cap to Assets Ratio 0.25
Asset Growth Rate (YoY) 6.7%
Total Assets CN¥39.83 Billion
Market Capitalization $9.95 Billion USD

Valuation Analysis

Below Book Valuation: The market values Sichuan Kelun Pharmaceutical Co Ltd's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Sichuan Kelun Pharmaceutical Co Ltd's assets grew by 6.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Sichuan Kelun Pharmaceutical Co Ltd (2007–2025)

The table below shows the annual total assets of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2025.

Year Total Assets Change
2025-12-31 CN¥39.83 Billion
≈ $5.83 Billion
+6.75%
2024-12-31 CN¥37.32 Billion
≈ $5.46 Billion
+2.36%
2023-12-31 CN¥36.45 Billion
≈ $5.33 Billion
+6.57%
2022-12-31 CN¥34.21 Billion
≈ $5.01 Billion
+8.45%
2021-12-31 CN¥31.54 Billion
≈ $4.62 Billion
-1.47%
2020-12-31 CN¥32.01 Billion
≈ $4.68 Billion
+1.67%
2019-12-31 CN¥31.49 Billion
≈ $4.61 Billion
+7.30%
2018-12-31 CN¥29.34 Billion
≈ $4.29 Billion
+4.85%
2017-12-31 CN¥27.99 Billion
≈ $4.10 Billion
+19.56%
2016-12-31 CN¥23.41 Billion
≈ $3.43 Billion
+3.66%
2015-12-31 CN¥22.58 Billion
≈ $3.30 Billion
+6.51%
2014-12-31 CN¥21.20 Billion
≈ $3.10 Billion
+18.14%
2013-12-31 CN¥17.95 Billion
≈ $2.63 Billion
+20.20%
2012-12-31 CN¥14.93 Billion
≈ $2.18 Billion
+42.67%
2011-12-31 CN¥10.47 Billion
≈ $1.53 Billion
+18.63%
2010-12-31 CN¥8.82 Billion
≈ $1.29 Billion
+164.65%
2009-12-31 CN¥3.33 Billion
≈ $487.78 Million
+25.50%
2008-12-31 CN¥2.66 Billion
≈ $388.68 Million
+48.62%
2007-12-31 CN¥1.79 Billion
≈ $261.53 Million
--

About Sichuan Kelun Pharmaceutical Co Ltd

SHE:002422 China Drug Manufacturers - General
Market Cap
$9.95 Billion
CN¥68.01 Billion CNY
Market Cap Rank
#2197 Global
#219 in China
Share Price
CN¥42.75
Change (1 day)
-0.02%
52-Week Range
CN¥28.83 - CN¥51.35
All Time High
CN¥51.35
About

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, ve… Read more